Login / Signup

Treatment-related neuroendocrine prostate cancer with BRCA2 germline mutation treated with olaparib.

Riko IkedaYoh MatsuokaMasaharu InoueAyataka IshikawaKiwamu AkagiYukio Kageyama
Published in: IJU case reports (2023)
mutations.
Keyphrases
  • prostate cancer
  • radical prostatectomy
  • dna repair
  • combination therapy
  • oxidative stress
  • dna damage
  • newly diagnosed